CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) indication: to reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to BH4-responsive phenylketonuria

The CADTH Canadian Drug Expert Committee (CDEC) recommends that sapropterin, in conjunction with a phenylalanine (Phe)-restricted diet, be reimbursed to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU)

Bibliographic Details

Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, October 26, 2016
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK533831
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa